Eli Lilly & Co Earnings - Q3 2026 Analysis & Highlights
The call focused on strong Q3 growth, expanding incretin demand and access, pipeline progress, manufacturing investment, and higher 2026 guidance, while management outlined qualitative drivers and headwinds for 2027.
Key financial results
Q3 revenue grew 39% year over year, an increase of nearly $7 billion; key product revenue rose by more than $6 billion.
Gross margin was 84.4%, up 80 basis points, reflecting favorable product mix and lower production costs, partly offset by lower realized prices.
Non-GAAP performance margin was 54.2%, up 5.9 percentage points year over year, driven by revenue growth.
Non-GAAP EPS was $7.48, including $4.57 of acquired IPR&D charges, compared with $7.02 in Q3 2025, including $0.71 of such charges.
Marketing, selling and administrative expenses increased 14%, while R&D expenses increased 23%, reflecting commercial investment and pipeline development, respectively.
Business segment results
The call did not provide revenue or profit figures for each business segment, but management said revenue from the oncology, immunology and neuroscience portfolio doubled year over year.
In immunology, Ebglyss worldwide revenue grew 59% year over year and continued to gain share of new prescriptions in US specialty dermatology.
In oncology, Jaypirca worldwide revenue increased 59%; Inluriyo exited Q3 with more than 60% share of new US prescriptions and 40% of total US prescriptions in its market.
In neuroscience, Kisunla revenue grew 175% year over year and maintained its US leadership position in amyloid-targeting therapies.
In cardiometabolic health, Mounjaro and Zepbound generated more than $16 billion in combined Q3 revenue and accounted for $6 billion of year-over-year growth.
Geographically, US revenue increased 34%; Europe grew 29% in constant currency; Japan grew 26%, China 62%, and the rest of the world 87% in constant currency.
Capital allocation
Lilly distributed $1.5 billion in dividends and executed $400 million in share repurchases during Q3.
The company broke ground on two US manufacturing facilities: a $6.5 billion facility in Houston and a $5 billion facility in Richmond.
The call did not state a Q3 capital-expenditure total or debt repayment amount.
Industry trends and dynamics
US total prescriptions in the incretin market grew 32% year over year; obesity incretin prescriptions rose 82%, while type 2 diabetes incretin prescriptions increased 8%.
International incretin gross sales increased 53% year over year, and Lilly’s share outside the US reached approximately 58%, nearly four percentage points higher than in Q2 2026.
Management described substantial remaining growth potential, noting that Lilly was reaching about 1 in 10 relevant patients in the US and 2 in 100 outside the US.
The Medicare GLP-1 Bridge program had enabled more than 0.5 million people to fill Lilly prescriptions since its July 1 launch; approximately 80% of treated Bridge patients were new to incretin therapy.
Management cited an external USC Schaeffer Center estimate that wider Medicare access to anti-obesity medicines could generate more than $20 billion in cumulative savings over 10 years.
Competitive landscape
Lilly medicines accounted for approximately 6 in 10 US obesity prescriptions and more than 7 in 10 injectable obesity prescriptions; Lilly also held more than 60% of the US type 2 diabetes incretin market.
Foundayo was selected by approximately 4 in 10 patients starting an oral obesity medicine, and its share of new US prescriptions was approaching 4 in 10.
In a head-to-head type 2 diabetes trial, retatrutide produced 2.2% A1C reduction and 20%–21% weight loss, compared with 1.8% and 9.4%, respectively, for 2 mg semaglutide.
Management said Lilly maintained international share and continued growing after generic launches in India, Brazil and Canada; it also described disciplined pricing for differentiated products.
Lilly said it aims for a tighter range of obesity-medicine pricing across markets than has historically been seen in other medicine categories.
Macroeconomic environment
The call did not provide a distinct outlook on inflation, tariffs, trade or recession; management identified net realized price and changes in sales-channel mix as business considerations instead.
Management expected net realized price to remain a headwind in 2027, more than offset by volume growth.
Growth opportunities and strategies
Lilly continued Foundayo’s international rollout, with launches in the UK, Mexico and Saudi Arabia during Q3; the medicine had launched in four countries and was under regulatory review in more than 40 additional countries.
US Foundayo new-patient numbers doubled quarter over quarter, and Lilly expected regulatory action for its type 2 diabetes use in Q4.
Lilly acquired AtaiBeckley and Merida Biosciences in Q3, adding neuroplastogen programs and a Phase 1 precision-immunology therapy, respectively.
Management said it had broken ground on two US manufacturing facilities to support long-term growth and described continued investment in R&D and commercial capabilities.
Lilly set a goal to reach as many people with obesity and related diseases in resource-limited settings as in high-income countries before 2040.
Management said it was pursuing a portfolio of obesity medicines with different potential roles, including Foundayo, tirzepatide, retatrutide, selective amylin medicines and EloraTZP.
Financial Guidance and Outlook
Lilly raised 2026 revenue guidance to $91 billion–$92 billion, non-GAAP performance margin guidance to 52%–52.5%, and non-GAAP EPS guidance to $35–$36.
Management said 2026 revenue included approximately $2 billion of one-time items, primarily milestone payments and changes in rebate and discount estimates, which it did not expect to recur.
For 2027, management expected continued US incretin volume growth, a full-year contribution from the Medicare Bridge program, and growth from Foundayo’s type 2 diabetes launch; outside the US, it expected Mounjaro’s leadership to continue and Foundayo to launch.
Management expected commercial access to remain relatively stable in 2027, with expanded Medicare and Medicaid coverage likely to be the principal access improvement; that channel mix could carry lower net prices per prescription.
The company planned to provide its formal 2027 financial guidance on the Q4 call in January.
